This company listing is no longer active
Jounce Therapeutics (21J) Stock Overview
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
21J Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Jounce Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.67 |
| 52 Week High | US$5.13 |
| 52 Week Low | US$0.53 |
| Beta | 0.75 |
| 1 Month Change | -3.47% |
| 3 Month Change | 61.43% |
| 1 Year Change | -64.83% |
| 3 Year Change | -62.22% |
| 5 Year Change | -88.59% |
| Change since IPO | -89.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 21J | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.5% | 0.8% | 1.2% |
| 1Y | -64.8% | 4.5% | 0.7% |
Return vs Industry: 21J underperformed the German Biotechs industry which returned -5.2% over the past year.
Return vs Market: 21J underperformed the German Market which returned -3.3% over the past year.
Price Volatility
| 21J volatility | |
|---|---|
| 21J Average Weekly Movement | 19.8% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 21J's share price has been volatile over the past 3 months.
Volatility Over Time: 21J's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 141 | n/a | jouncetx.com |
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy.
Jounce Therapeutics, Inc. Fundamentals Summary
| 21J fundamental statistics | |
|---|---|
| Market cap | €89.78m |
| Earnings (TTM) | -€46.20m |
| Revenue (TTM) | €74.40m |
Is 21J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 21J income statement (TTM) | |
|---|---|
| Revenue | US$82.00m |
| Cost of Revenue | US$54.80m |
| Gross Profit | US$27.20m |
| Other Expenses | US$78.12m |
| Earnings | -US$50.92m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 33.17% |
| Net Profit Margin | -62.10% |
| Debt/Equity Ratio | 0% |
How did 21J perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/05 19:26 |
| End of Day Share Price | 2023/05/04 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jounce Therapeutics, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Cory Kasimov | J.P. Morgan |